ROSY-T: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Osimertinib (TAGRISSO) and are Judged by the Investigator to Clinically Benefit From Continued Treatment

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501528-58-00

Acronym

D5161N00007

Enrollment

Registered

2023-08-09

Start date

2023-10-16

Completion date

Unknown

Last updated

2025-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Various tumor types depending on the parent study

Brief summary

SAEs and serious AESIs reported until 28 days after the last dose of study treatment

Interventions

DRUGTAGRISSO 80 mg film-coated tablets

DRUGTAGRISSO 40 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
SAEs and serious AESIs reported until 28 days after the last dose of study treatment	—

Countries

France, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026